PharmAI
PharmAI GmbH is a German biotech spin-out company specializing in AI-powered software solutions for drug discovery. Their proprietary DiscoveryEngine technology uses knowledge-based structure analysis of protein binding sites and drug-target interactions to optimize high-throughput screening libraries, diversify chemical scaffolds, and identify off-target effects early in drug development. By leveraging 3D protein structure data, binding affinity, and deep learning, PharmAI accelerates drug candidate identification with high precision and scaffold diversity, significantly improving hit rates and reducing costs. The company serves pharmaceutical and biotech clients, offering rapid, accurate, and comprehensive screening services covering over 2 million compounds and 90% of known human drug targets. Their technology is supported by extensive pre-computation and collaborations with research institutions and industry partners, positioning PharmAI as an innovative player in computational drug discovery.
PharmAI
PharmAI GmbH is a German biotech spin-out company specializing in AI-powered software solutions for drug discovery. Their proprietary DiscoveryEngine technology uses knowledge-based structure analysis of protein binding sites and drug-target interactions to optimize high-throughput screening libraries, diversify chemical scaffolds, and identify off-target effects early in drug development. By leveraging 3D protein structure data, binding affinity, and deep learning, PharmAI accelerates drug candidate identification with high precision and scaffold diversity, significantly improving hit rates and reducing costs. The company serves pharmaceutical and biotech clients, offering rapid, accurate, and comprehensive screening services covering over 2 million compounds and 90% of known human drug targets. Their technology is supported by extensive pre-computation and collaborations with research institutions and industry partners, positioning PharmAI as an innovative player in computational drug discovery.